Australia's Avecho Biotech up on Vit. K injection development progress

Avecho Biotechnology

12/01/2023 03:58

** Shares of Avecho Biotechnology  AVE.AX  leap as much as
23.1% to A$0.016, their highest level since Jan. 4 
    ** Biotech firm says U.S.-based Athenex  ATNX.O  presented
AVE's TPM-enhanced phytonadione injectable, its Vitamin K
injection, to the U.S. FDA in a pre-IND meeting request 
    ** If FDA feedback is positive, ATNX to sign licence and
development deal for the product, and develop it further till
registration for commercialisation in the U.S. 
    ** AVE ended 2022 flat 
 (Reporting by Harshita Swaminathan)
 ((Harshita.Swaminathan@thomsonreuters.com))